PMID- 19418204
OWN - NLM
STAT- MEDLINE
DCOM- 20121231
LR  - 20211020
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 58
IP  - 7
DP  - 2009 Jul
TI  - Lovastatin inhibits antigen-induced airway eosinophilia without affecting the 
      production of inflammatory mediators in mice.
PG  - 363-9
LID - 10.1007/s00011-009-0043-5 [doi]
AB  - OBJECTIVE AND DESIGN: Statins have been proposed as a novel treatment of 
      respiratory diseases. To determine the beneficial effects of statins on allergic 
      bronchial asthma, the effect of systemic treatment with lovastatin on 
      antigen-induced airway inflammation was investigated. SUBJECTS: Male BALB/c mice 
      were used. TREATMENTS: Mice were sensitized and repeatedly challenged with 
      ovalbumin (OA) antigen to induce asthmatic response. Animals were also treated 
      with lovastatin (4 mg/kg/day, i.p.) once a day prior to and during the antigen 
      inhalation period. METHODS: Inflammatory cell counts and levels of interleukin 
      (IL)-4, IL-13, eotaxin, thymus and activation-regulated chemokine and leukotriene 
      B(4) (LTB(4)) in bronchoalveolar lavage (BAL) fluids were measured. RESULTS: 
      Significant increases in eosinophils and levels of the T helper 2 cytokines, 
      chemokines and LTB(4) in BAL fluids in association with the increments of total 
      and OA-specific immunoglobulin E (IgE) in sera were observed in the repeatedly 
      antigen-challenged mice. The airway eosinophilia was ameliorated by lovastatin, 
      whereas it had no significant effect on the levels of these inflammatory 
      mediators or IgE. CONCLUSION: Lovastatin may be beneficial for the treatment of 
      allergic inflammatory diseases in the airways, such as allergic bronchial asthma.
FAU - Chiba, Y
AU  - Chiba Y
AD  - Department of Pharmacology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, 
      Shinagawa-ku, Tokyo 142-8501, Japan. chiba@hoshi.ac.jp
FAU - Sato, S
AU  - Sato S
FAU - Misawa, M
AU  - Misawa M
LA  - eng
PT  - Journal Article
DEP - 20090506
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antigens)
RN  - 0 (Cytokines)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Inflammation Mediators)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - 9LHU78OQFD (Lovastatin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Antigens
MH  - Asthma/*drug therapy/immunology
MH  - Bronchoalveolar Lavage Fluid/cytology/immunology
MH  - Cell Count
MH  - Cytokines/immunology
MH  - Disease Models, Animal
MH  - Eosinophilia/*drug therapy/immunology
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/therapeutic use
MH  - Immunoglobulin E/blood/immunology
MH  - Inflammation Mediators/immunology
MH  - Leukotriene B4/immunology
MH  - Lovastatin/pharmacology/*therapeutic use
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin
MH  - Pneumonia/*drug therapy/immunology
EDAT- 2009/05/07 09:00
MHDA- 2013/01/01 06:00
CRDT- 2009/05/07 09:00
PHST- 2008/08/31 00:00 [received]
PHST- 2009/04/09 00:00 [accepted]
PHST- 2009/03/02 00:00 [revised]
PHST- 2009/05/07 09:00 [entrez]
PHST- 2009/05/07 09:00 [pubmed]
PHST- 2013/01/01 06:00 [medline]
AID - 10.1007/s00011-009-0043-5 [doi]
PST - ppublish
SO  - Inflamm Res. 2009 Jul;58(7):363-9. doi: 10.1007/s00011-009-0043-5. Epub 2009 May 
      6.